In this arteriolar niche, breast cancer stem cells and arteriolar endothelial cells cross-talk using a well-known signaling pathway. Targeting this pathway may offer therapeutic potential.More than 43,000 American women will die from breast cancer this year. Most of those deaths will occur after the cancer has spread to other organs, a process called metastasis. This involves at least five major steps. Two early steps are invasion of the basement membrane and cell migration, and then a movement of the cancer cell through the wall and into a blood vessel or lymph vessel to begin its journey.
By examining estrogen receptor-positive breast cancer tissues from women, Bin Ren, M.D., Ph.D., associate professor of surgery at the University of Alabama at Birmingham, has now found, for the first time, evidence of a heretofore unnoticed location for breast cancer stem cells in the tumor microenvironment at the cell migration stage. The cancer stem cells appear to accumulate near a tumor arteriole, the small branch of the artery just before capillaries.
Ren calls this the arteriolar niche, and he says it may be an important tumor vascular microenvironment to prepare cancer cells for metastasis, not only in breast cancer but also in other highly angiogenic cancers such as glioblastoma, lung cancer, malignant melanoma and pancreatic neuroendocrine cancers.
Breast cancer stem cells — a sub-population of the cancer cells — are the most aggressive for metastasis, growth and drug resistance.
In Ren’s study, published in the journal Communications Biology (Nature), the researchers found evidence of cross-talk between the breast cancer stem cells and arteriolar endothelial cells, using the lysophosphatidic acid/protein kinase D, or the LPA/PKD-1 signaling pathway. This signaling pathway was observed to promote cancer stem cell features and potential development of the arteriolar niche by using human breast cancer tissues, mouse breast cancer models, and vascular endothelial cells from genetically engineered mice and cell cultures.
From their findings, the researchers propose a mechanistic model. Bidirectional interactions — using LPA/PKD-1 signaling — promote arteriolar differentiation of endothelial cells within the tumor microenvironment, self-renewal of cancer stem cells, and breast cancer progression and metastasis, likely through differential regulation of CD36 transcription.
Bin Ren, M.D., Ph.D.
(Photography: Nik Layman)“We think this niche is important, and it may exist in other cancers with a rich growth of new blood vessels,” Ren said. “These studies indicate that the LPA/PKD-1 signaling may play an essential role in tumor progression and spread to other organs such as the lungs by nurturing the development of an arteriolar niche to enhance cancer stem cell self-renewal and directly promoting stemness features of cancer cells. Targeting the LPA/PKD-1 CD36 signaling pathway may have therapeutic potential to curb tumor progression and metastasis by disrupting the arteriolar niche and effectively eliminating cancer stem cells.”
Co-first authors for the study, “Development of an arteriolar niche and self-renewal of breast cancer stem cells by lysophosphatidic acid/protein kinase D signaling,” are Yinan Jiang, Yichen Guo and Jinjin Hao, UAB Department of Surgery.
Other co-authors are Rachael Guenter, Adam Beck, Reagan Hattaway, Helen Krontiras and Herbert Chen, UAB Department of Surgery; Justin Lathia, Cleveland Clinic; Douglas Hurst, UAB Department of Pathology; Qiming Jane Wang, University of Pittsburgh School of Medicine; Yehe Liu, Case Western Reserve University, Cleveland, Ohio; Qi Cao, University of Maryland School of Medicine, Baltimore, Maryland; and Roy Silverstein, Medical College of Wisconsin, Milwaukee, Wisconsin.
Support came from the UAB School of Medicine, American Cancer Society grant 86-004-26, American Heart Association grant 13SDG14800019, Ann’s Hope Foundation grant FP00011709 and National Institutes of Health grant HL136423.
At UAB, Ren holds the William D. Jordan Jr., M.D., Endowed Professorship in Vascular Sciences.